Behavioral Genetics of Mood-Induced Smoking

情绪诱发吸烟的行为遗传学

基本信息

项目摘要

DESCRIPTION (provided by applicant): "Behavioral Genetics of Mood-Induced Smoking" Controlled laboratory studies reliably show that negative mood manipulations of various kinds acutely increase smoking reinforcement. However, very few studies have identified individual differences that moderate mood-induced smoking, and only one, a recent report by us, has examined genetic associations. The primary aim of this proposal is to validate our prior, preliminary data on genetic associations with increases in smoking due to negative mood, a potentially important novel phenotype for nicotine dependence. Dependent smokers (N=200) will participate in two virtually identical lab sessions, differing only in induction of negative vs. positive mood via a validated procedure to robustly induce mood (one mood per session, sessions in counter-balanced order). They will ad lib smoke their preferred brand of cigarettes (to maximize generalizability) during mood induction each session. Differences in smoking reinforcement (latency and amount of smoking) between the negative and positive mood conditions, i.e. mood-induced smoking, will be related to the dopamine and mu opioid receptor gene variants identified in our preliminary study. These include: dopamine D4 receptor (DRD4 VNTR), dopamine D2 receptor (DRD2 C957T SNP [rs6277] and DRD2/ANKK1 TaqIA SNP [rs1800497]), the dopamine transporter (SLC6A3 VNTR), and the mu opioid receptor exon 1 SNP (OPRM1 A118G [rs1799971]). In secondary aims, we will examine genetic associations with smoking reward, affect, and related measures, as well as other individual differences in mood-induced smoking, including subject sex, depression history, distress tolerance, and severity of nicotine dependence. Our prior study and past productive collaborations between the PI and co-I demonstrate the strong feasibility of this proposal. Results of this innovative project may identify smokers potentially at greater risk for relapse due to negative mood and may guide research on mechanisms behind mood-induced smoking. Our procedures could be used to test the efficacy of medications to attenuate mood-induced smoking, thereby reducing vulnerability of some smokers to mood-related relapse. This project also could be a prototype for future research that combines rigorous behavioral pharmacology methodology and genetics to identify individual variation in drug reinforcement due to situational influences. PUBLIC HEALTH RELEVANCE: Negative mood increases smoking behavior and leads to relapse after a quit attempt. Controlled laboratory studies show that negative mood manipulations of various kinds (e.g. stressors) acutely increase smoking behavior. However, very few studies have identified individual differences in mood-induced smoking, and only one, a preliminary study by us, examined genetic associations with mood-induced smoking. This project will validate our preliminary observations, which may identify smokers particularly vulnerable (or resistant) to smoking relapse due to negative mood. Results may guide research on genetics of environmental influences on smoking behavior and other drug abuse, and perhaps guide research on the mechanisms behind mood-induced smoking.
描述(由申请人提供):“情绪诱导吸烟的行为遗传学”对照实验室研究可靠地表明,各种负面情绪操纵会急剧增加吸烟强化。然而,很少有研究确定了个体差异,缓和情绪诱导吸烟,只有一个,我们最近的一份报告,研究了遗传关联。该提案的主要目的是验证我们先前的初步数据,这些数据与由于消极情绪导致的吸烟增加有关,这是尼古丁依赖的一种潜在重要的新表型。依赖性吸烟者(N=200)将参加两个几乎相同的实验室阶段,不同之处仅在于通过经验证的程序诱导消极情绪与积极情绪,以强烈诱导情绪(每个阶段一种情绪,以平衡顺序进行)。在每次情绪诱导过程中,他们会随意抽自己喜欢的牌子的香烟(以最大限度地提高概括性)。消极和积极情绪条件(即情绪诱导的吸烟)之间吸烟强化(潜伏期和吸烟量)的差异将与我们初步研究中鉴定的多巴胺和μ阿片受体基因变体相关。其中包括:多巴胺D4受体(DRD 4 VNTR)、多巴胺D2受体(DRD 2 C957 T SNP [rs6277]和DRD 2/ANKK 1 TaqIA SNP [rs 1800497])、多巴胺转运蛋白(SLC 6A 3 VNTR)和μ阿片受体外显子1 SNP(OPRM 1 A118 G [rs 1799971])。在次要目标中,我们将研究与吸烟奖励,影响和相关措施的遗传关联,以及情绪诱导吸烟的其他个体差异,包括受试者性别,抑郁史,痛苦耐受性和尼古丁依赖的严重程度。我们之前的研究以及PI和co-I之间过去富有成效的合作证明了该提案的强大可行性。这个创新项目的结果可能会发现吸烟者由于消极情绪而有更大的复发风险,并可能指导对情绪诱导吸烟机制的研究。我们的程序可用于测试药物减轻情绪诱导的吸烟的功效,从而减少一些吸烟者因情绪相关而复发的可能性。该项目也可以成为未来研究的原型,结合严格的行为药理学方法和遗传学,以确定由于情境影响而导致的药物强化的个体差异。 公共卫生相关性:消极情绪会增加吸烟行为,并导致戒烟尝试后复发。对照实验室研究表明,各种负面情绪操纵(例如压力源)会急剧增加吸烟行为。然而,很少有研究确定了情绪诱发吸烟的个体差异,只有一项研究,即我们的初步研究,研究了情绪诱发吸烟的遗传关联。该项目将验证我们的初步观察,这可能会发现吸烟者特别容易(或抵抗)吸烟复吸由于消极情绪。研究结果可能会指导环境对吸烟行为和其他药物滥用影响的遗传学研究,并可能指导情绪诱导吸烟背后机制的研究。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH Alan PERKINS其他文献

KENNETH Alan PERKINS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH Alan PERKINS', 18)}}的其他基金

First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence
具有一流戒烟和节欲机制的新候选药物的首次人体临床开发
  • 批准号:
    10452567
  • 财政年份:
    2021
  • 资助金额:
    $ 23.56万
  • 项目类别:
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence
具有一流戒烟和节欲机制的新候选药物的首次人体临床开发
  • 批准号:
    10620310
  • 财政年份:
    2021
  • 资助金额:
    $ 23.56万
  • 项目类别:
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence
具有一流戒烟和节欲机制的新候选药物的首次人体临床开发
  • 批准号:
    10328576
  • 财政年份:
    2021
  • 资助金额:
    $ 23.56万
  • 项目类别:
Reinforcement-enhancing effects of NRT
NRT 的强化作用
  • 批准号:
    9084517
  • 财政年份:
    2014
  • 资助金额:
    $ 23.56万
  • 项目类别:
Reinforcement-enhancing effects of NRT
NRT 的强化作用
  • 批准号:
    8754436
  • 财政年份:
    2014
  • 资助金额:
    $ 23.56万
  • 项目类别:
Threshold Dose for Nicotine Discrimination in Cigarettes
香烟中尼古丁歧视的阈剂量
  • 批准号:
    8573038
  • 财政年份:
    2013
  • 资助金额:
    $ 23.56万
  • 项目类别:
Threshold Dose for Nicotine Discrimination in Cigarettes
香烟中尼古丁歧视的阈剂量
  • 批准号:
    8720746
  • 财政年份:
    2013
  • 资助金额:
    $ 23.56万
  • 项目类别:
Reinforcement-enhancing effects of nicotine
尼古丁的强化作用
  • 批准号:
    8087136
  • 财政年份:
    2011
  • 资助金额:
    $ 23.56万
  • 项目类别:
Reinforcement-enhancing effects of nicotine
尼古丁的强化作用
  • 批准号:
    8302290
  • 财政年份:
    2011
  • 资助金额:
    $ 23.56万
  • 项目类别:
Behavioral Genetics of Mood-Induced Smoking
情绪诱发吸烟的行为遗传学
  • 批准号:
    7761384
  • 财政年份:
    2009
  • 资助金额:
    $ 23.56万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 23.56万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了